StockNow
Log in
U.S. Markets

Edwards Lifesciences (EW) Q2 2026 (USD) Adj. EPS 0.78 (exp. 0.74), Revenue 1.74bln (exp. 1.70bln)

StockNow breaking-news AI analysis

Edwards Lifesciences surpassed Q2 2026 expectations behind strong TAVR and TMTT growth, while providing a Q3 guidance range that largely aligns with existing market consensus.

News detail

Sees Q3 Adj. EPS USD 0.71-0.77 (exp. 0.75) Sees Q3 rev. USD 1.63bln-1.71bln (exp. 1.69bln)

1 stocks

What do investors think?

Curious what other investors think?Log in to see reactions and join the conversation.
Log in to view reactions

StockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.

Today's market highlights

A selection of stories drawing attention in the market.

See more
U.S. Markets

Eli Lilly (LLY) Q2 2026 (USD): Adj. EPS 8.38 (exp. 6.01), Revenue 23bln (exp. 20.7bln)

LLYGeopolitics

Gulf official tells CNN “50:50” chance US and Iran could reach deal by Friday, CNN reports; Iranian delegation does not include IRGC, which would need to sign off on details of provisional agreement

Geopolitics

The draft agreed to by Iranian and Omani negotiators awaits final approval from Iran’s supreme leader, two regional officials told The Associated Press on Wednesday